What does BESINS HEALTHCARE PHARMTECH do?

BESINS HEALTHCARE PHARMTECH is registered with the CBE as active in: Vervaardiging van geneesmiddelen. Public Limited, started on 30 October 2019, 1 establishment.

What is the address of BESINS HEALTHCARE PHARMTECH?

The registered office of BESINS HEALTHCARE PHARMTECH is located at Rue Louis Plescia 9, 4102 Seraing.

Is BESINS HEALTHCARE PHARMTECH still active?

Yes. According to the CBE (29 October 2026) BESINS HEALTHCARE PHARMTECH is active, legal situation “Normale toestand”, started on 30 October 2019.

Is BESINS HEALTHCARE PHARMTECH registered on Peppol?

Yes, BESINS HEALTHCARE PHARMTECH is registered on the Peppol network with ID 0208:0736939187.

What is the enterprise number of BESINS HEALTHCARE PHARMTECH?

The enterprise number of BESINS HEALTHCARE PHARMTECH is BE0736939187.

When was BESINS HEALTHCARE PHARMTECH founded?

BESINS HEALTHCARE PHARMTECH was founded on 30 October 2019.

Who are the directors of BESINS HEALTHCARE PHARMTECH?

According to the 2025 annual accounts, the directors of BESINS HEALTHCARE PHARMTECH are: Jean Marie Rakic, Corpar, Rudi Meurs, Sparaxis, Noshaq, Robert Taub, Marc Foidart.

Is BESINS HEALTHCARE PHARMTECH a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 30 October 2019; 5 annual accounts filed, latest fiscal year 2025; 7 directors known from the annual account.

How much profit did BESINS HEALTHCARE PHARMTECH make in 2025?

BESINS HEALTHCARE PHARMTECH recorded a loss after taxes of € 6,302,304 in financial year 2025.

What is the revenue of BESINS HEALTHCARE PHARMTECH?

In its most recent annual accounts (2025), BESINS HEALTHCARE PHARMTECH reported revenue of € 7,572,112.

How much does an employee at BESINS HEALTHCARE PHARMTECH earn?

The average wage cost per full-time employee at BESINS HEALTHCARE PHARMTECH was € 99,700 in 2025: staff costs of € 4.1 million for 41.1 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does BESINS HEALTHCARE PHARMTECH have?

According to the 2025 annual accounts, BESINS HEALTHCARE PHARMTECH has 41.1 full-time equivalents (FTE).

BESINS HEALTHCARE PHARMTECH (Public Limited) - Seraing

Dossier BESINS HEALTHCARE PHARMTECH, printed on 29 October 2026 from databakkes.be/en/0736939187/besins-healthcare-pharmtech. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Negative equity NBB

More debt than assets in 2 of the last 4 fiscal years.
Two loss years in a row NBB

Negative result in 2024 and 2025.
Tight liquidity NBB

Cash and receivables cover 14 % of short-term debt in 2025; threshold 65 %.

Financials

Financial year 2025

BESINS HEALTHCARE PHARMTECH from Seraing, company number BE0736939187, closed financial year 2025 with a result of € -6.3 million after tax. For that financial year BESINS HEALTHCARE PHARMTECH recorded revenue of € 7.6 million and equity of € -9.5 million. Compared with financial year 2024, the result moved from € -5.3 million to € -6.3 million. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on July 15, 2026.

What it is worth Caution

€ -9.5 million

▼ € 6.7 million vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Loss Caution

€ -6.3 million

▼ 18 % more loss than in 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 121,901

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Caution

Loss, nothing to pay out

Reserves fell to € -14.4 million.

People and assets in 2025

Full-time equivalents

41.1

▲ 7.6 vs 2024

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 4.1 million

▲ 25% vs 2024

€ 99,700 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 14.2 million

▼ 10% vs 2024

Of which on lease € 13.9 million.

Debts at end 2025

Bank debt ≈ 4 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 21.6 million

▼ 2% vs 2024

€ 5 million is repaid this year. At this pace the long-term loan is gone in ≈ 4 years.

Owed to suppliers

€ 1.4 million

▼ 31% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Wages and social charges

€ 410,762

▲ 14% vs 2024

Wages, holiday pay and social contributions still to pay. No outstanding taxes.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Revenue	-	-	€ 6,041,044 Revenue 2024: € 6,041,044 First fiscal year in the series	€ 7,572,112 Revenue 2025: € 7,572,112 ▲ 25% vs 2024 (€ 6,041,044) Favourable step	▲ 25%
Gross margin	€ 3,066,304 Gross margin 2022: € 3,066,304 First fiscal year in the series	€ 2,545,931 Gross margin 2023: € 2,545,931 ▼ 17% vs 2022 (€ 3,066,304) Unfavourable step	€ 725,320 Gross margin 2024: € 725,320 ▼ 72% vs 2023 (€ 2,545,931) Unfavourable step	€ 1,235,449 Gross margin 2025: € 1,235,449 ▲ 70% vs 2024 (€ 725,320) Favourable step	▲ 70%
Profit after taxes	€ -784,973 Profit after taxes 2022: € -784,973 First fiscal year in the series	€ -2,816,767 Profit after taxes 2023: € -2,816,767 ▼ € 2 million vs 2022 (€ -784,973) Unfavourable step	€ -5,322,074 Profit after taxes 2024: € -5,322,074 ▼ € 2.5 million vs 2023 (€ -2,816,767) Unfavourable step	€ -6,302,304 Profit after taxes 2025: € -6,302,304 ▼ € 980,230 vs 2024 (€ -5,322,074) Unfavourable step	▼ € 980,230
Equity	€ 6,046,581 Equity 2022: € 6,046,581 First fiscal year in the series	€ 2,668,980 Equity 2023: € 2,668,980 ▼ 56% vs 2022 (€ 6,046,581) Unfavourable step	€ -2,806,174 Equity 2024: € -2,806,174 ▼ € 5.5 million vs 2023 (€ 2,668,980) Unfavourable step	€ -9,493,314 Equity 2025: € -9,493,314 ▼ € 6.7 million vs 2024 (€ -2,806,174) Unfavourable step	▼ € 6.7 million
Total debts	€ 33,584,323 Total debts 2022: € 33,584,323 First fiscal year in the series	€ 27,603,401 Total debts 2023: € 27,603,401 ▼ 18% vs 2022 (€ 33,584,323) Favourable step	€ 29,936,106 Total debts 2024: € 29,936,106 ▲ 8% vs 2023 (€ 27,603,401) Unfavourable step	€ 33,164,603 Total debts 2025: € 33,164,603 ▲ 11% vs 2024 (€ 29,936,106) Unfavourable step	▲ 11%
Cash	€ 568,468 Cash 2022: € 568,468 First fiscal year in the series	€ 790,969 Cash 2023: € 790,969 ▲ 39% vs 2022 (€ 568,468) Favourable step	-	€ 121,901 Cash 2025: € 121,901 First fiscal year in the series
Land & buildings	-	-	-	€ 66,050 Land & buildings 2025: € 66,050 First fiscal year in the series
Retained profit	€ -1,838,099 Retained profit 2022: € -1,838,099 First fiscal year in the series	€ -2,816,767 Retained profit 2023: € -2,816,767 ▼ € 978,668 vs 2022 (€ -1,838,099) Unfavourable step	€ -8,138,841 Retained profit 2024: € -8,138,841 ▼ € 5.3 million vs 2023 (€ -2,816,767) Unfavourable step	€ -14,441,146 Retained profit 2025: € -14,441,146 ▼ € 6.3 million vs 2024 (€ -8,138,841) Unfavourable step	▼ € 6.3 million
Bank debt	€ 30,491,486 Bank debt 2022: € 30,491,486 First fiscal year in the series	€ 19,417,017 Bank debt 2023: € 19,417,017 ▼ 36% vs 2022 (€ 30,491,486) Favourable step	€ 22,013,749 Bank debt 2024: € 22,013,749 ▲ 13% vs 2023 (€ 19,417,017) Unfavourable step	€ 21,617,911 Bank debt 2025: € 21,617,911 ▼ 2% vs 2024 (€ 22,013,749) Favourable step	▼ 2%
Balance sheet total	€ 39,630,904 Balance sheet total 2022: € 39,630,904 First fiscal year in the series	€ 30,272,381 Balance sheet total 2023: € 30,272,381 ▼ 24% vs 2022 (€ 39,630,904) Unchanged	€ 27,129,932 Balance sheet total 2024: € 27,129,932 ▼ 10% vs 2023 (€ 30,272,381) Unchanged	€ 23,671,289 Balance sheet total 2025: € 23,671,289 ▼ 13% vs 2024 (€ 27,129,932) Unchanged	▼ 13%
Employees (FTE)	27.4 Employees (FTE) 2022: 27.4 First fiscal year in the series	26.4 Employees (FTE) 2023: 26.4 ▼ 1 vs 2022 (27.4) Unchanged	33.5 Employees (FTE) 2024: 33.5 ▲ 7.1 vs 2023 (26.4) Unchanged	41.1 Employees (FTE) 2025: 41.1 ▲ 7.6 vs 2024 (33.5) Unchanged	▲ 7.6

Key figures of BESINS HEALTHCARE PHARMTECH, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to BESINS HEALTHCARE PHARMTECH?

What happened at BESINS HEALTHCARE PHARMTECH in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

2029 Jean Marie Rakic stepped down as director. NBB
2029 Rudi Meurs stepped down as director. NBB
2029 Noshaq stepped down as director. NBB
2029 Robert Taub stepped down as director. NBB
2029 Marc Foidart stepped down as director. NBB
Jul 15, 2026 New annual accounts for financial year 2025: loss of € 6.3 million. Source: NBB ↗
2026 Corpar stepped down as director. NBB
2026 Sparaxis stepped down as director. NBB

In short

From € 784,973 loss in 2022 to € 6.3 million loss in 2025.

Paid € 35,321 in corporate taxes since 2022.

On average € 30,100 of value added per employee in 2025.

Original PDFs at the National Bank ↗

Management

Fund+ 15.3%

QBIC II FUND ARKIV 4.1%

Ophtalmologie Chirurgicale Van Cauwenberge Rakic 3.3%

OUSIA 0.2%

The stake of Fund+, QBIC II FUND ARKIV, Ophtalmologie Chirurgicale Van Cauwenberge Rakic, OUSIA, WTW AG comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

BESINS HEALTHCARE PHARMTECH

LSP2 41%

The shares are held by Fund+ (15.3%), QBIC II FUND ARKIV (4.1%), Ophtalmologie Chirurgicale Van Cauwenberge Rakic (3.3%), OUSIA (0.2%) and WTW AG (0%). It owns 41% of LSP2 itself.